Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial

Juan F. Iglesias1, Marco Valgimigli2, Federico Carbone3,4, Nathalie Lauriers5, Pier-Giorgio Masci5, Sophie Degrauwe1

1Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland
2Department of Cardiology, Cardiocentro Ticino, Lugano, Switzerland
3First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Italy
4IRCCS Ospedale Policlinico San Martino Genoa, Italian Cardiovascular Network, Genoa, Italy
5Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland

Abstract

Background: Morphine reduces absorption and delays action onset of potent oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction (STEMI). We sought to determine the differential effects of fentanyl compared to morphine on the pharmacodynamics and pharmacokinetics of ticagrelor in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Methods: PERSEUS (NCT02531165) was a prospective, single-center, open-label, randomized controlled study. Patients with STEMI who required analgesia were randomly assigned in a 1:1 ratio to treatment with intravenous fentanyl or morphine after ticagrelor loading dose (LD) administration. The primary endpoint was platelet reactivity at 2 hours after ticagrelor LD assessed by P2Y12 reaction units (PRU).

Results: The study was prematurely stopped in June 2017 after enrolment of 38 out of 56 planned patients. PRU at 2 hours following ticagrelor LD was 173.3 ± 89.7 in the fentanyl group and 210.3 ± 76.4 in the morphine group (p = 0.179). At 4 hours, PRU was significantly lower among patients treated with fentanyl as compared to those treated with morphine (90.1 ± 97.4 vs. 168.0 ± 72.2; p = 0.011). Maximal plasma concentrations of ticagrelor and its active metabolite AR-C124910XX tended to be delayed and numerically lower among patients treated with morphine compared to fentanyl. Total exposures to ticagrelor and AR-C124910XX within 6 hours after ticagrelor LD were numerically greater among patients treated with fentanyl compared to those treated with morphine.

Conclusions: In patients with STEMI undergoing primary PCI, fentanyl did not improve platelet inhibition at 2 hours after ticagrelor pre-treatment compared with morphine. Fentanyl may, however, accelerate ticagrelor absorption and increase platelet inhibition at 4 hours compared to morphine.

Key words: fentanyl, pharmacodynamics, pharmacokinetics, ST-segment elevation myocardial infarction, ticagrelor
Introduction

Dual antiplatelet therapy combining acetysalicylic acid (ASA) and a P2Y_{12} receptor antagonist is a cornerstone in the pharmacological treatment of patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)[1]. Early optimal P2Y_{12} receptor inhibition has been shown to improve coronary reperfusion before primary PCI and clinical outcomes compared to a delayed P2Y_{12} inhibition strategy in patients with STEMI [2]. However, platelet inhibitory effects induced by potent oral P2Y_{12} receptor antagonists are delayed in patients with STEMI [3, 4]. Recent pharmacological studies have demonstrated that morphine further reduces absorption, delays onset of action, and decreases antiplatelet effects of oral P2Y_{12} inhibitors among STEMI patients [4–7], which potentially results in an increased risk of stent-related adverse outcomes [8].

Methods

Study design and patient population

PERSEUS was an investigator-initiated, prospective, single-center, open-label, randomized controlled trial. A detailed description of the study rationale and design has been previously published [14]. Briefly, patients with STEMI undergoing primary PCI within 12 hours of symptoms’ onset were eligible for inclusion. Key inclusion and exclusion criteria have been reported previously [14]. Patients on chronic P2Y_{12} receptor antagonist or oral anticoagulation therapy, or who received glycoprotein IIb/IIIa inhibitors were excluded. In addition, patients with medical conditions that may adversely affect gastrointestinal absorption and metabolic activation of oral P2Y_{12} receptor inhibitors, including comatose patients or those with cardiogenic shock, were excluded. All patients were pre-treated with ASA (loading dose [LD] 500 mg), ticagrelor (LD 180 mg), and unfractionated heparin (LD 5000 IU or 70–100 IU per kg of body weight) at the time of STEMI diagnosis. Patients requiring analgesia for pain relief (visual analogue scale [VAS] score ≥ 3) were randomly assigned in a 1:1 ratio to treatment with intravenous fentanyl (50–100 mg) or morphine (4–8 mg) using a centralized telephone treatment allocation. Additional doses of fentanyl (25 mg, every 2–5 min) or morphine (2 mg, every 5–15 min) were administered to achieve adequate analgesia (VAS score < 3). All patients underwent primary PCI according to institutional standards. The choice of vascular access site, periprocedural anticoagulation regimen, and procedural techniques was left to the discretion of the treating physician. After primary PCI, all patients received a maintenance dose of ASA (100 mg daily) indefinitely. A ticagrelor maintenance dose (90 mg twice daily) was initiated 12 hours after the LD and was recommended for at least 12 months. The study protocol complied with the Declaration of Helsinki. The study protocol was approved by the local Ethics Committee at Lausanne University Hospital, Switzerland (Project ID: PB 2016-00291). All enrolled patients provided written informed consent for participation. The trial was registered with ClinicalTrials.gov, identifier NCT02531165.

Pharmacodynamic assessments

Blood samples were collected at baseline and at 1, 2, 4, 6, and 12 hours after ticagrelor LD admin-
Platelet reactivity was determined as P2Y<sub>12</sub> reaction units (PRU) using the VerifyNow<sup>®</sup> P2Y<sub>12</sub> function assay (Accumetrics, Inc., San Diego, California, USA) at 1, 2, 4, 6, and 12 hours, and platelet reactivity index (PRI) using the Vasodilator-Stimulated-phosphoprotein Phosphorylation (VASP) assay (Biocytex, Inc., Marseille, France) at 1, 2, and 4 hours after ticagrelor LD administration [14]. High on-treatment platelet reactivity (HTPR) was defined as PRU $\geq 240$ or PRI $\geq 50\%$ [15].

Pharmacokinetic assessments

Plasma concentrations of ticagrelor and its major active metabolite AR-C124910XX were determined by a blinded external laboratory (Covance Laboratories, Indianapolis, Indiana, USA) at 1, 2, 4, 6, and 12 hours after ticagrelor pre-treatment using high-performance liquid chromatography combined with tandem mass spectrometry detection in the negative ion mode after protein precipitation extraction. A detailed description of blood samples collection and preparation has been reported previously [13]. Baseline ticagrelor and AR-C124910XX plasma concentrations were presumed to be zero because subjects on chronic P2Y<sub>12</sub> receptor inhibitors were excluded. The lower limits of quantification for ticagrelor and AR-C124910XX were 1 ng/mL and 2.5 ng/mL, respectively.

Study endpoints

The primary endpoint was platelet reactivity assessed by PRU at 2 hours after ticagrelor LD administration. Prespecified secondary endpoints include platelet reactivity assessed by PRU at 1, 4, 6, and 12 hours after ticagrelor LD, the proportion of patients with HTPR at 1, 2, 4, 6, and 12 hours after ticagrelor LD, the peak plasma concentration ($C_{\text{max}}$) of ticagrelor and AR-C124910XX at 1, 2, 4, 6, and 12 hours after ticagrelor LD, the time to peak plasma concentration ($T_{\text{max}}$) for ticagrelor and AR-C124910XX, the area under the plasma concentration-time curve for ticagrelor and AR-C124910XX during the first 6 hours after ticagrelor LD ($\text{AUC}_{0-6}$), the proportion of patients with thrombolysis in myocardial infarction (TIMI) grade 3 flow in the infarct-related artery before primary PCI, and the proportion of patients with $\geq 70\%$ ST-segment elevation resolution after primary PCI. Data collection and monitoring have been described previously [14]. Study endpoints were independently adjudicated by a clinical events committee blinded to treatment assignment.

Sample size calculation

At the time of the study design, there was no reference study examining the effects of fentanyl on the pharmacodynamics and pharmacokinetics of P2Y<sub>12</sub> receptor inhibitors in patients with STEMI treated with primary PCI. Based on the results of previous studies [4–7], we assumed a mean PRU value of 190 at 2 hours after ticagrelor administration in STEMI patients undergoing primary PCI after receiving analgesia with morphine. We presumed that platelet reactivity assessed by PRU at 2 hours after ticagrelor loading dose administration would be lower in patients receiving fentanyl as compared to morphine (PRU 160 ± 40; absolute platelet reactivity difference, 30 PRU; relative platelet reactivity difference, 16%) due to differential involvement of μ-opioid receptor sites and responsible regions between fentanyl and morphine, which results in varying effects on gastrointestinal motility and degrees of induced dysmotility [14]. Assuming a two-sided statistical significance level of 0.05 and 95% confidence interval (CI), we calculated that enrolment of a total of 56 patients (28 in both study groups) would provide 80% power to demonstrate a significant difference in PRU values at 2 hours after ticagrelor LD administration between treatment arms.

Statistical analysis

All analyses were performed according to the intention-to-treat principle. The results are presented as percentages for categorical variables and mean ± standard deviation or medians (interquartile range [IQR]) for continuous data with normal and skewed distributions, respectively. Comparisons between categorical data were performed using Fisher’s exact test, whereas Student’s t-test and the Mann-Whitney test were used for comparisons of continuous and ordinal data, as appropriate. Comparisons between paired samples were performed using paired sample t-test or Wilcoxon sum rank test. Statistical significance was considered for p values < 0.05. All statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism version 5.0 for Windows (GraphPad Software, La Jolla CA, USA).

Results

Between December 18, 2015 and June 22, 2017, 38 patients were included and randomly assigned to treatment with fentanyl ($n = 19$) or morphine
The study was prematurely stopped due to a slower than anticipated patient enrolment rate after inclusion of 38 (68%) of the 56 patients planned. Patient baseline and procedural characteristics were similar between the two treatment groups (Table 1). Median age was 68.6 ± 13.1 years in the fentanyl group and 65.2 ± 16.2 years in the morphine group (p = 0.46). Median reperfusion delays from STEMI diagnosis to primary PCI and from ticagrelor loading dose administration to primary PCI did not differ between patients treated with fentanyl or morphine. Infarct-related coronary artery characteristics and final myocardial infarct size, as assessed by peak troponin levels, were comparable between the two treatment groups. Finally, mean self-reported VAS pain score was similar in the fentanyl and the morphine groups, both at the time of randomization (4.8 ± 5.5 vs. 6.3 ± 1.7; p = 0.50) and before PCI (2.4 ± 2.6 vs. 1.9 ± 2.3; p = 0.57).

Pharmacodynamic assessment
The primary endpoint, mean PRU at 2 hours after ticagrelor LD, was 173.3 ± 89.7 in patients treated with fentanyl and 201.3 ± 76.4 among those receiving morphine (p = 0.179). Mean PRU values were significantly lower with fentanyl at 4 hours compared with morphine (90.1 ± 128.5 vs. 74.6 ± 63.4 ng/mL; p = 0.011) among patients treated with fentanyl as compared to those receiving morphine (Table 3). Median Tmax for ticagrelor (6 h; IQR 4–12 vs. 12 h; IQR 4–12; p = 0.325) and AR-C124910XX (6 h; IQR 6–12; p = 0.070) were similar among patients treated with fentanyl and morphine (Table 3). Total exposures to ticagrelor (1386 ng × h/mL; IQR 96–2765 vs. 579 ng × h/mL; IQR 74–1108; p = 0.108) and AR-C124910XX (293 ng × h/mL; IQR 17–881 vs. 71 ng × h/mL; IQR 17–225; p = 0.080) within 6 hours of ticagrelor pre-treatment were numerically greater among patients treated with fentanyl versus morphine (Table 3).

Coronary perfusion outcomes
TIMI grade < 3 flow in the infarct-related artery before primary PCI was found in 18 (94.7%) patients in the fentanyl group and in 18 (94.7%) patients in the morphine group (p = 1.00) (Fig. 3). Following ticagrelor LD administration, ST-segment elevation resolution < 70% after primary PCI was observed in 9 (60%) patients in the fentanyl group and in 8 (50%) patients in the morphine group (p = 0.47) (Fig. 3).

Discussion
In the PERSEUS randomized trial, fentanyl did not improve platelet inhibition at 2 hours after ticagrelor LD administration compared to morphine among patients with STEMI undergoing primary PCI. Despite the premature study termination resulting in loss of statistical power, there was consistent pharmacodynamic and pharmacokinetic evidence that fentanyl may be associated with a more favorable ticagrelor absorption profile than morphine. The use of fentanyl in symptomatic patients with STEMI, who were pre-treated with...
ticagrelor, may accelerate ticagrelor absorption, and result in significantly increased platelet inhibition at 4 hours compared to morphine. To our knowledge, PERSEUS represents the first direct randomized comparison between fentanyl and morphine with regards to the pharmacodynamic and pharmacokinetic response to ticagrelor in STEMI patients requiring analgesia.

Rapid-onset and effective platelet P2Y<sub>12</sub> receptor inhibition represents the mainstay of pharmacological treatment in patients with STEMI undergoing primary PCI [1]. However, antiplatelet

### Table 1. Patient baseline and procedural characteristics.

| Characteristics                                      | Fentanyl (n = 19) | Morphine (n = 19) | P     |
|-------------------------------------------------------|-------------------|-------------------|-------|
| Age [years]                                           | 68.6 ± 13.1       | 65.2 ± 16.2       | 0.46  |
| Male                                                  | 13 (68.4%)        | 14 (73.7%)        | 0.72  |
| Body mass index [kg/m²]                               | 26.7 ± 5.7        | 26.5 ± 3.7        | 0.93  |
| Hypertension                                          | 8 (42.1%)         | 10 (52.6%)        | 0.51  |
| Dyslipidemia                                          | 7 (36.9%)         | 8 (42.1%)         | 0.74  |
| Diabetes mellitus                                     | 3 (15.8%)         | 3 (15.8%)         | 1.00  |
| Current smoker                                        | 9 (47.4%)         | 8 (42.1%)         | 0.74  |
| Prior coronary artery disease                         | 1 (5.3%)          | 3 (15.7%)         | 0.29  |
| Prior myocardial infarction                           | 1 (5.3%)          | 4 (21.1%)         | 0.15  |
| Prior PCI                                             | 0 (0%)            | 3 (15.7%)         | –     |
| Prior CABG                                            | 0 (0%)            | 0 (0%)            | –     |
| Prior stroke                                          | 0 (0%)            | 0 (0%)            | –     |
| Peripheral arterial disease                           | 1 (5.3%)          | 2 (10.5%)         | 0.55  |
| Chronic kidney disease                                | 2 (10.5%)         | 2 (10.5%)         | 1.00  |
| Medication at admission:                              |                   |                   |       |
| Oral anticoagulation                                  | 0 (0%)            | 1 (5.3%)          | –     |
| Acetylsalicylic acid                                  | 4 (21.1%)         | 7 (36.8%)         | 0.28  |
| Statin                                                | 5 (26.3%)         | 7 (36.8%)         | 0.48  |
| Beta-blocker                                          | 2 (10.5%)         | 4 (21.1%)         | 0.37  |
| ARB/ACE inhibitor                                     | 4 (21.1%)         | 4 (21.1%)         | 1.00  |
| Vital signs:                                          |                   |                   |       |
| Systolic BP [mmHg]                                    | 128.9 ± 27.1      | 121.1 ± 21.2      | 0.33  |
| Diastolic BP [mmHg]                                   | 73.0 ± 15.2       | 70.7 ± 11.3       | 0.60  |
| Heart rate [bpm]                                      | 77.5 ± 20.3       | 75.9 ± 12.6       | 0.77  |
| STEMI diagnosis to primary PCI time [min] (median, IQR)| 108.0 (24.2)      | 105.0 (22.4)      | 0.74  |
| Ticagrelor loading dose to primary PCI time [min] (median, IQR) | 72.5 (32.4)   | 84.5 (20.3)     | 0.17  |
| Cardiogenic shock                                     | 2 (10.5%)         | 1 (5.3%)          | 0.52  |
| Infarct-related coronary vessel:                      |                   |                   |       |
| Left anterior descending artery                       | 7 (36.8%)         | 8 (42.1%)         | 0.74  |
| Left circumflex artery                                | 4 (21.1%)         | 3 (15.8%)         | 0.67  |
| Right coronary artery                                 | 8 (42.1%)         | 7 (36.8%)         | 0.74  |
| Other                                                 | 0 (0%)            | 1 (5.3%)          | –     |
| Peak troponin level [ng/L] (median, IQR)              | 6719.9 ± 6463.6   | 6211.4 ± 8934.4   | 0.84  |
| Visual Analogue Scale score:                          |                   |                   |       |
| At randomization                                      | 4.8 ± 5.5         | 6.3 ± 1.7         | 0.50  |
| Before PCI                                            | 2.4 ± 2.6         | 1.9 ± 2.3         | 0.57  |

Values are mean ± standard deviation, n (%), or median [interquartile range (IQR)]. ACE — angiotensin converting enzyme; ARB — angiotensin receptor blockers; BP — blood pressure; CABG — coronary artery bypass grafting; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction.
The inhibitory effects induced by potent oral P2Y$_{12}$ receptor antagonists are substantially delayed in STEMI patients [3, 4] owing to impaired gastrointestinal absorption [16]. The results of the present analysis are consistent with previous pharmacological studies indicating that intravenous opioid agents delay the absorption and the onset of action of orally administered P2Y$_{12}$ receptor antagonists in patients undergoing primary PCI for STEMI, which results in reduced plasma concentrations, delayed antiplatelet effects, and increased platelet reactivity of oral P2Y$_{12}$ receptor inhibitors [3, 7]. In the IMPRESSION randomized trial [7], morphine co-administration with ticagrelor was associated with reduced total exposure to ticagrelor and its active metabolite, which resulted in delayed and attenuated maximal plasma concentrations of ticagrelor compared to placebo among patients with acute myocardial infarction. The adverse pharmacological effects of morphine on oral P2Y$_{12}$ receptor antagonists are likely caused by the inhibition of normal muscular activity of the gastrointestinal tract in patients with STEMI [17, 18]. Our findings confirm that the delayed and reduced antiplatelet effects of potent oral P2Y$_{12}$ receptor inhibitors in STEMI patients treated with intravenous opioid agents are mainly attributed to an altered pharmacokinetic profile, which reduces total exposure to oral P2Y$_{12}$ receptor inhibitors within the first hours after LD administration.

The clinical implications of the pharmacological interaction between μ-opioid receptor agonists and P2Y$_{12}$ receptor inhibitors in patients with acute coronary syndrome (ACS) remain controversial. In the FAST-MI registry, in-hospital and 1-year rates of major adverse ischemic outcomes were similar between STEMI patients who received, as compared to those who did not receive, prehospital morphine, but the risk of myocardial re-infarction during admission was significantly higher among patients pretreated with morphine [19]. Conversely, morphine was associated with higher risk-adjusted in-hospital and 30-day rates of ischemic events among patients with non ST-elevation ACS pretreated with clopidogrel in the EARLY ACS trial [20], thus disclosing the need for future research on alternatives to morphine in ACS patients requiring analgesia. Different strategies have been proposed

### Table 2. Pharmacodynamic assessment with P2Y$_{12}$ reaction units and platelet reactivity index after ticagrelor loading dose (LD) administration in patients treated with fentanyl versus morphine.

|                      | Fentanyl (n = 19) | Morphine (n = 19) | P    |
|----------------------|------------------|------------------|------|
| **P2Y$_{12}$ reaction units** |                  |                  |      |
| At baseline          | 188.89 ± 47.51   | 205.00 ± 49.16   | 0.331|
| At 1 hour post LD    | 187.84 ± 87.56   | 202.47 ± 66.87   | 0.566|
| At 2 hours post LD   | 173.26 ± 89.69   | 201.32 ± 76.41   | 0.179|
| At 4 hours post LD   | 90.11 ± 97.42    | 168.00 ± 72.24   | 0.011|
| At 6 hours post LD   | 79.33 ± 89.10    | 122.17 ± 80.34   | 0.139|
| At 12 hours post LD  | 51.33 ± 53.29    | 83.33 ± 63.81    | 0.112|
| **Platelet reactivity index** |                  |                  |      |
| At 1 hour post LD    | 56.52 ± 26.93    | 76.35 ± 16.39    | 0.013|
| At 2 hours post LD   | 54.27 ± 27.45    | 64.82 ± 24.28    | 0.237|
| At 4 hours post LD   | 34.38 ± 27.42    | 52.12 ± 30.60    | 0.086|

Values are mean ± standard deviation

![Figure 2. High on-treatment platelet reactivity rates following ticagrelor loading dose administration in patients treated with fentanyl versus morphine; HTPR — high on-treatment platelet reactivity as assessed by the VerifyNow P2Y$_{12}$ assay. Histograms represent rates.](596.png)
to bridge the initial gap in platelet inhibition and overcome high on-treatment residual platelet reactivity associated with the use of oral P2Y12 inhibitors in STEMI patients, including upstream P2Y12 receptor antagonist administration [21], escalating P2Y12 receptor inhibitor LD regimens [16], intravenous P2Y12 receptor antagonists [22], use of glycoprotein IIb/IIIa inhibitors [23], or co-administration of a prokinetic agent [24]. To date, it remained uncertain whether intravenous opioid agents such as fentanyl have similar adverse pharmacological effects on orally administered P2Y12 receptor antagonists in patients with STEMI. Recent evidence indicates that μ-opioid receptor

Table 3. Pharmacokinetic assessment of ticagrelor and AR-C124910XX after ticagrelor loading dose (LD) administration in patients treated with fentanyl versus morphine.

|                | Fentanyl (n = 19) | Morphine (n = 19) | P     |
|----------------|-------------------|-------------------|-------|
| **Ticagrelor** |                   |                   |       |
| T_{max} [h]    | 6 (4–12)          | 12 (4–12)         | 0.325 |
| C_{max} [ng/mL]| 184.8 ± 361.6     | 32.3 ± 56.7       | 0.078 |
| at 1 hour post LD |                   |                   |       |
| at 2 hours post LD |                 |                   |       |
| at 4 hours post LD |                 |                   |       |
| at 6 hours post LD |                 |                   |       |
| at 12 hours post LD |                |                   |       |
| AUC_{0-6} [ng × h/mL] | 1386 (96–2765) | 579 (74–1108)     | 0.108 |
| **AR-C124910XX** |                   |                   |       |
| T_{max} [h]    | 6 (4–12)          | 12 (6–12)         | 0.070 |
| C_{max} [ng/mL]| 22.7 ± 44.9       | 24.5 ± 13.4       | 0.095 |
| at 1 hour post LD |                   |                   |       |
| at 2 hours post LD |                 |                   |       |
| at 4 hours post LD |                 |                   |       |
| at 6 hours post LD |                 |                   |       |
| at 12 hours post LD |                |                   |       |
| AUC_{0-6} [ng × h/mL] | 293 (17–881) | 71 (17–225)       | 0.080 |

Values are mean ± standard deviation or median [interquartile range (IQR)]; AUC_{0-6} — area under the plasma concentration-time curve at 6 hours after ticagrelor loading dose; C_{max} — peak plasma concentration; T_{max} — time to peak plasma concentration

Figure 3. Coronary perfusion outcomes before primary percutaneous coronary intervention (PCI) in patients treated with fentanyl versus morphine. Proportion of patients with thrombolysis in myocardial infarction (TIMI) flow grade 0 to 3 in the infarct-related artery (A), and with or without ≥ 70% ST-segment elevation resolution (B) before primary PCI; *p-value for comparison of TIMI flow grade 3 between the fentanyl and morphine groups = 0.34; #p-value for comparison of > 70% ST-segment resolution after PCI between the fentanyl and morphine groups = 0.58.
agonists have differential pharmacological profiles and exert their effects by involvement of different μ-opioid receptor sites and varying degrees of gastrointestinal dysmotility [25]. Fentanyl is a potent, fast-acting, and effective intravenous synthetic opioid agent [9], which displays different pharmacological dose-response curves and mitigates gastrointestinal motility inhibition compared to morphine [25], hence theoretically improving the absorption and the bioavailability of orally administered drugs. In the PACIFY trial, fentanyl has been shown to reduce plasma concentration and delay antiplatelet effects of ticagrelor compared with placebo, but the study only included patients undergoing PCI for chronic coronary syndrome [11, 12]. To the best of our knowledge, PERSEUS is the first head-to-head randomized trial designed to specifically compare the pharmacological effects of fentanyl versus morphine in patients with STEMI undergoing primary PCI after pre-treatment with a potent oral P2Y12 receptor inhibitor. The present study suggests potential differences in the pharmacological responses to ticagrelor between STEMI patients who received fentanyl or morphine for pain relief after ticagrelor pre-treatment. Overall, peak and time-to-peak plasma concentrations for ticagrelor and its major active metabolite AR-C124910XX after ticagrelor pre-treatment tended to be numerically higher and faster, respectively, among STEMI patients treated with fentanyl as compared to those receiving morphine. In addition, total exposures to ticagrelor and AR-C124910XX within 6 hours of ticagrelor pre-treatment were numerically greater among patients treated with fentanyl versus morphine. The observed numerical differences in ticagrelor pharmacokinetic profiles between fentanyl- and morphine-treated patients yielded a significantly increased platelet inhibition at 4 hours after ticagrelor pre-treatment among patients treated with fentanyl as compared to those receiving morphine. Interestingly, the analgesic effect of fentanyl-treated patients was similar to the effect observed with morphine, which lends further support to the preferential use of fentanyl rather than morphine in symptomatic STEMI patients undergoing primary PCI.

Limitations of the study

The results of the present study should be interpreted bearing in mind several limitations. Due to the premature termination of the trial and the smaller than anticipated sample size, the study results should be interpreted with appropriate caution and considered as hypothesis-generating. Notwithstanding, our pharmacodynamic findings suggest potential for an improved platelet inhibition at 4 hours with fentanyl after ticagrelor LD administration among STEMI patients as compared to morphine. The present study was not powered to assess pain outcomes between the fentanyl and morphine groups. As per study protocol, we defined HTPR as PRU ≥ 240 assessed by VerifyNow® platelet function assay according to consensus evidence available at the time of the study design [15]. However, we found similar results with regards to platelet reactivity when defining HTPR as PRU ≥ 208. Finally, this study was not powered for clinical endpoints, and larger studies are needed to explore whether the observed differences in ticagrelor pharmacodynamic and pharmacokinetic profiles induced by fentanyl versus morphine may translate into different clinical outcomes.

Conclusions

In patients with STEMI undergoing primary PCI after ticagrelor pre-treatment, fentanyl did not improve platelet inhibition at 2 hours compared with morphine. Taking into account the loss of power due to premature study termination, we found pharmacodynamic and pharmacokinetic evidence that fentanyl has the potential to reduce ticagrelor absorption delay and improve platelet inhibition compared to morphine. Future, properly powered studies should investigate the comparative clinical effects of fentanyl versus morphine in symptomatic STEMI patients undergoing primary PCI.

Acknowledgments

The authors would like to acknowledge F. Dami, L. Alberio and O. Muller (Lausanne University Hospital, Switzerland), E. Ciavatta (Morges Hospital, Switzerland), J. Rossat and J. Ombelli (Yverdon Hospital, Switzerland), T. Bolognini, M. Burion and I. Renaud (Riviera-Chablais Hospital, Switzerland), and F. Rigamonti (Geneva University Hospitals, Switzerland) for their valuable collaboration and contribution to the study.

Funding

PERSEUS was supported by a dedicated research grant from AstraZeneca AG, Switzerland. The principal (J.F.I.) and co-principal (S.D.) investigators are solely responsible for the design and conduct of the study, and all study analyses. The funding source was not involved in the study design, data collection, and management, and played
no role in the study data analysis or interpretation. The data supporting these findings are available from the corresponding author on reasonable request.

Conflict of interest: Juan F. Iglesias reports research grants to the institution and personal fees from AstraZeneca during the conduct of the study; grants and personal fees from Biotronik, Philips Volcano, and AstraZeneca, and personal fees from Terumo, Medtronic, and Cardinal Health, outside the submitted work; Marco Valgimigli reports grants and personal fees from Abbott, Terumo, and AstraZeneca, personal fees from Bayer, Daiichi Sankyo, Amgen, Alvimedica, Idorsia, Coreflow, Vifor, Bristol-Myers Squibb, and iVascular, and grants from Medicare, outside the submitted work; Sophie Degrauwé reports grants and personal fees from Biotronik, outside the submitted work. All other authors declare no conflicts of interest.

References

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177, doi: 10.1093/eurheartj/ehx389, indexed in PubMed: 29886621.

2. Bellemain-Appaix A, Bégué C, Blatt DL, et al. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention. 2018; 14(1): 78–85, doi: 10.4244/EIJ-D-17-00568.x, indexed in PubMed: 29046319.

3. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012; 5(6): 797–804, doi: 10.1161/CIRCINTERVENTIONS.111.997233, indexed in PubMed: 23169985.

4. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013; 61(15): 1601–1606, doi: 10.1016/j.jacc.2013.01.024, indexed in PubMed: 23500251.

5. Hobl EL, Stimpfl T, Ehner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014; 63(7): 630–635, doi: 10.1016/j.jacc.2013.10.068, indexed in PubMed: 24315907.

6. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-segment acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015; 8(1), doi: 10.1161/CIRCINTERVENTIONS.114.001593, indexed in PubMed: 25552565.

7. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3): 245–252, doi: 10.1093/eurheartj/ehv547, indexed in PubMed: 26491112.

8. Furtado RHM, Nicolau JC, Guo J, et al. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol. 2020; 75(3): 289–300, doi: 10.1016/j.jacc.2019.11.035, indexed in PubMed: 31978987.

9. Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017; 77(7): 747–763, doi: 10.1007/s40263-017-0727-z, indexed in PubMed: 28337672.

10. Lavi S, Jolly SS, Bainbridge D, et al. Sedation, analgesia, and anaesthesia variability in laboratory-based cardiac procedures: an international survey. Can J Cardiol. 2014; 30(6): 627–632, doi: 10.1016/j.cjca.2014.03.034, indexed in PubMed: 24882533.

11. McEvo J, Brahim K, Kicker T, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention. Circulation. 2018; 137(3): 307–309, doi: 10.1161/circulationa ha.117.031678, indexed in PubMed: 29046319.

12. Ibrahim K, Shaib R, Goli RR, et al. Fentanyl delays the platelet inhibition: effects of oral ticagrelor: full report of the PACIFY randomized clinical trial. Thromb Haemost. 2018; 118(8): 1409–1418, doi: 10.1055/s-0038-1668682, indexed in PubMed: 29072861.

13. Iglesias JF, Valgimigli M, Carbone F, et al. Effects of fentanyl versus morphine on ticagrelor-induced platelet inhibition in patients with ST-segment elevation myocardial infarction: the PERSEUS randomized trial. Circulation. 2020; 142(25): 2479–2481, doi: 10.1161/CIRCULATIONAHA.120.040287, indexed in PubMed: 33347326.

14. Degrauwé S, Roffi M, Mauriers N, et al. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 158–163, doi: 10.1093/ehjcvp/pvy031, indexed in PubMed: 30101278.

15. Bonello L, Tantry US, Marucci R, et al. Consensus and future directions on the definition of high-on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56(12): 919–933, doi: 10.1016/j.jacc.2010.04.047, indexed in PubMed: 20982644.

16. Franchi F, Rollini F, Cho JR, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015; 8(11): 1457–1467, doi: 10.1016/j.jcin.2015.02.030, indexed in PubMed: 26404190.

17. Nimmo WS, Heading RC, Wilson J, et al. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol. 1975; 2(6): 509–513, doi: 10.1111/j.1365-2125.1975.tb00568.x, indexed in PubMed: 9953.

18. Giannopoulos G, Defteros S, Kolokathis F, et al. P2Y12 receptor antagonists and morphine: a dangerous liaison? . Circ Cardiovasc Pharmacol. 1975; 2(6): 509–513, doi: 10.1016/j.cjca.2014.03.034, indexed in PubMed: 24882533.

19. Puymirat E, Lamhaut L, Bonnet N, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J.
20. Furtado RHM, Nicolau JC, Guo J, et al. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol. 2020; 75(3): 289–300, doi: 10.1016/j.jacc.2019.11.035, indexed in Pubmed: 31978867.

21. Montalescot G, van ‘t Hof AW, Montalescot G, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371(11): 1016–1027, doi: 10.1056/NEJMoa1407024, indexed in Pubmed: 2517921.

22. Franchi F, Rollini F, Rivas A, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2019; 139(14): 1661–1670, doi: 10.1161/CIRCULATIONAHA.118.038317, indexed in Pubmed: 30630941.

23. Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012; 5(3): 268–277, doi: 10.1016/j.jcin.2012.01.006, indexed in Pubmed: 22440491.

24. Saad M, Meyer-Saraei R, de Waha-Thiele S, et al. Impact of morphine treatment with and without metoclopramide coadministration on ticagrelor-induced platelet inhibition in acute myocardial infarction: the randomized monAMI trial. Circulation. 2020; 141(16): 1354–1356, doi: 10.1161/CIRCULATIONAHA.119.042816, indexed in Pubmed: 32310699.

25. Mori T, Shibasaki Y, Matsumoto K, et al. Mechanisms that underlie μ-opioid receptor agonist-induced constipation: differential involvement of μ-opioid receptor sites and responsible regions. J Pharmacol Exp Ther. 2013; 347(1): 91–99, doi: 10.1124/jpet.112.204313, indexed in Pubmed: 23902939.